Leonard A. Valentino, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. A preventive approach to the management of severe hemophilia A.
   Valentino LA.
   Clin Adv Hematol Oncol. 2012
   2012 Mar
   10(3):185-6. No abstract available.
   
2. Management of joint bleeding in hemophilia.
   Simpson ML, Valentino LA.
   Expert Rev Hematol. 2012
   2012 Aug
   5(4):459-68.
   
3. Recombinant FIXFc: a novel therapy for the royal disease?
   Valentino LA.
   Expert Opin Biol Ther.
   2011 Oct
   11(10):1361-8
   
4. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
   Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF.
   Blood.
   2011 Nov 22
   
5. Venous access in the management of hemophilia
   Valentino LA, Kawji M, Grygotis M
   Blood Rev
   2011 Jan
   25(1):11-5
   
6. Assessment of blood-induced arthritis causes friction
   Valentino LA, Hakobyan N
   Haemophilia
   2011 Jan
   17(1):e242-3; doi: 10.1111/j.1365-2516.2010.02374.x.
   
7. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy
   Valentino LA
   J Thromb Haemost
   2010 Sep
   8(9):1895-902; doi: 10.1111/j.1538-7836.2010.03962.x
   
8. Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report
   Beier UH, Schmidt ML, Hast H, Kecskes S, Valentino LA
   J Med Case Reports
   2010 Mar 19
   4:92
   
9. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors
   Valentino LA
   Haemophilia
   2010 Mar
   16(2):263-71
   
10. Novel drugs to treat hemophilia
    Valentino LA, Ismael Y, Grygotis M
    Expert Opin Emerg Drugs
    2010 Dec
    15(4):597-613
    
11. The Fourth Annual Meeting of the International Network for Pediatric Hemophilia: Current Challenges and Recommendations in the Clinical Care of Children with Hemophilia.
    Ljung R, van den Berg M, Valentino LA, Manco-Johnson M.
    Transfus Med Hemother.
    2010
    37(4):209-212
    
12. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A
    Valentino LA, Recht M, Dipaola J, Shapiro AD, Pipe SW, Ewing N, Urgo J, Bullock T, Simmons M, Deguzman C
    Haemophilia
    2009 May
    15(3):718-26
    
13. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series
    Valentino LA
    Haemophilia
    2009 May
    15(3):733-42
    
14. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
    Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Ettingshausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C
    Haemophilia
    2009 Jul
    15(4):959-65
    
15. Prevention of haemarthrosis in a murine model of acute joint bleeding
    Valentino LA, Hakobyan N, Kazarian T, Sorensen BB, Tranholm M
    Haemophilia
    2009 Jan
    15(1):314-9
    
16. Controversies regarding the prophylactic management of adults with severe haemophilia A
    Valentino LA
    Haemophilia
    2009 Dec
    15 Suppl 2:5-18, quiz 19-22
    
17. Recombinant activated factor VII as a temporary reversal agent for warfarin anticoagulation: a cautionary report on an off-label application.
    Kalainov DM, Valentino LA.
    Am J Orthop (Belle Mead NJ).
    2008 Nov
    37(11):572-4
    
18. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes
    Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA
    Haemophilia
    2008 Jul
    14(4):804-9
    
19. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
    Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE.
    Blood.
    2008 Dec 1
    112(12):4532-41
    
20. Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues
    Valentino LA, Hakobyan N, Enockson C
    Semin Hematol
    2008 Apr
    45(2 Suppl 1):S50-7
    

• To watch a brief video of Leonard A. Valentino, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• Investigating people who have blood problems is a really interesting and rewarding area of medicine. It’s very detective-like. So there’s people who come in with particular problems that nobody’s been able to solve before. And we’re able to do that through a very sophisticated laboratory approach, as well as our comprehensive team of health care providers who can evaluate these patients on an ongoing basis.

  Hemophilia is frequently diagnosed in young children, especially when it’s severe disease. They’ll present with either bruising or with joint bleeding. People who have Von Willebrand disease, they’ll present with bruising or nose bleeding. And then women can have heavy periods as well. Through the use of specialized medications that both enhance blood clotting — either the replacement of Von Willebrand factor or the defective blood clotting protein in hemophilia — we can ameliorate many of those symptoms.